MADRIGAL PHARMACEUTICALS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Revenue from Contract with Customer, Excluding Assessed Tax of $364.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $364.25M, a 71.17% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $311.34M, a 126.84% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $321.08M, a 210.77% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $287.27M, a 362.03% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $958.40M, a 432.05% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $180.13M.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $364.25M 10-Q · filed 2026-07-30 | $675.59M 10-Q · filed 2026-07-30 | $996.67M derived: sum of 3 quarters · filed 2026-07-30 | $1.28B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $311.34M 10-Q · filed 2026-05-06 | $632.42M derived: sum of 2 quarters · filed 2026-05-06 | $919.69M derived: sum of 3 quarters · filed 2026-05-06 | $1.13B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $321.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $608.35M derived: sum of 2 quarters · filed 2026-02-19 | $821.15M derived: sum of 3 quarters · filed 2026-07-30 | $958.40M 10-K · filed 2026-02-19 |
| 2025-09-30 | $287.27M 10-Q · filed 2025-11-04 | $500.07M derived: sum of 2 quarters · filed 2026-07-30 | $637.32M 10-Q · filed 2025-11-04 | $740.64M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $212.80M 10-Q · filed 2026-07-30 | $350.05M 10-Q · filed 2026-07-30 | $453.37M derived: sum of 3 quarters · filed 2026-07-30 | $515.55M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $137.25M 10-Q · filed 2026-05-06 | $240.57M derived: sum of 2 quarters · filed 2026-05-06 | $302.75M derived: sum of 3 quarters · filed 2026-05-06 | $317.38M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $103.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $165.50M derived: sum of 2 quarters · filed 2026-02-19 | $180.13M derived: sum of 3 quarters · filed 2026-02-19 | $180.13M 10-K · filed 2026-02-19 |
| 2024-09-30 | $62.17M 10-Q · filed 2025-11-04 | $76.81M derived: sum of 2 quarters · filed 2025-11-04 | $76.81M 10-Q · filed 2025-11-04 | $76.81M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $14.64M 10-Q · filed 2025-08-05 | $14.64M 10-Q · filed 2025-08-05 | $14.64M derived: sum of 3 quarters · filed 2026-02-19 | $14.64M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |